Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026
Seeking Alpha ·
Earnings Call Insights: Summit Therapeutics (SMMT) Q2 2026 Robert Duggan (Co-CEO & Executive Chairman) said, "we expand our clinical development plan and prepare for commercialization in anticipation of a decision from the FDA on our BLA towards the end of this year," and highlighted
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
451 participants
Related News
- Alphabet Just Revealed a $94 Billion Stake in SpaceX -- and It Can't Sell a Single Share Yet
- Why Tesla Stock Crashed Today
- Amazon Fell 4.6% Today Because Other Companies Said They Would Spend More Money. It Reports July 30.
- Coinbase Calls AI Payments a High-Conviction Bet as Agent Checkout Goes Live
- Stripe Plans to Acquire PayPal for $53 Billion. Here's What That Could Mean for Crypto Investors.
- TSLA Stock Sinks Toward Worst Week This Year After Weak Q2 — But CEO Elon Musk Is A 'Big Fan' Of His Insightful Retail Investor Army
